Sagent Pharmaceuticals, Inc.
1901 N. Roselle Road
Suite 700
Schaumburg
Illinois
60195-3176
United States
Tel: 866-625-1618
Website: http://www.sagentpharma.com/
176 articles about Sagent Pharmaceuticals, Inc.
-
Sagent Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Levetiracetam Injection, USP Due to Lack of Sterility Assurance
11/19/2021
Sagent Pharmaceuticals, Inc. today announced the voluntary nationwide recall of four lots of Levetiracetam Injection, USP, to the user level.
-
Pfizer, Sagent Pharmaceuticals and Merck are preparing their antiviral pills against SARS-CoV-2 and are showing promise in new clinical trials.
-
Sagent Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Phenylephrine Hydrochloride Injection, USP, 10 mg/mL Due to Potential Lack of Sterility Assurance
3/11/2021
Sagent Pharmaceuticals, Inc. today announced the voluntary nationwide recall of three lots of Phenylephrine Hydrochloride Injection, USP (10 mg/mL)
-
Sagent Pharmaceuticals Announces Start of NIAID-Sponsored Study Investigating COVID-19 Treatments in Outpatients
2/12/2021
Sagent Pharmaceuticals, a Nichi-Iko Group Company, announced today that Camostat mesilate (Camostat), is one of four therapies being added to the existing ACTIV-2 Adaptive Platform Treatment Trial
-
Sagent Pharmaceuticals Launches Phase 2 Trial to Evaluate Camostat Mesilate for COVID-19 Treatment
11/11/2020
Sagent Pharmaceuticals, a Nichi-Iko Group Company, announced today that it has launched its Phase 2 CAMELOT trial to evaluate the safety and efficacy of Camostat Mesilate (Camostat) for the treatment of COVID-19 in high-risk outpatients and has begun enrolling patients
-
Sagent Pharmaceuticals Announces FDA Acceptance of Omega Manufacturing Site
9/5/2019
Nichi-Iko Pharmaceutical Co., Ltd. ("Nichi-Iko") and Sagent Pharmaceuticals, Inc., a Nichi-Iko Group Company ("Sagent"), a leader of specialty pharmaceutical products with an emphasis on the injectable market, today announced that their Canadian subsidiary, Omega Laboratories Limited ("Omega"), has been found acceptable for manufacturing FDA-approved products in its initial Establishment Inspection Report issued by the U.S. FDA.
-
Sagent Pharmaceuticals Issues Voluntary Nationwide Recall of Ketorolac Tromethamine Injection, USP, 60mg/2mL (30mg per mL) Due to Lack of Sterility Assurance
4/30/2019
Sagent Pharmaceuticals, Inc. announced the voluntary nationwide recall of one lot of Ketorolac Tromethamine Injection, USP, 60mg/2mL.
-
Sagent Pharmaceuticals Announces Acquisition of Raleigh Manufacturing Site
3/1/2019
Nichi-Iko Pharmaceutical Co., Ltd. and Sagent Pharmaceuticals, Inc. announced that Sagent has acquired an FDA-approved manufacturing site in Raleigh, North Carolina, from Xellia Pharmaceuticals.
-
Sagent Pharmaceuticals Issues Voluntary Nationwide Recall of Methylprednisolone Sodium Succinate for Injection, USP, 40mg, 125mg, and 1g Due to High Out of Specification Impurity Results
3/5/2018
Sagent Pharmaceuticals, Inc. today announced the voluntary nationwide recall of ten lots of Methylprednisolone Sodium Succinate for Injection, USP, 40mg, 125mg, and 1g.
-
Nichi-Iko Announces Results Of Tender Offer To Purchase All Of The Outstanding Shares Of Common Stock Of Sagent Pharma
8/29/2016
-
Sagent Pharma Initiates A Nationwide Voluntary Recall Of Oxacillin For Injection, USP, 10 G Due To Presence Of Iron Oxide Particulate Matter
8/18/2016
-
Nichi-Iko Announces Expiration Of HSR Waiting Period For Proposed Acquisition Of Sagent Pharma
8/9/2016
-
Shepard Vision, A Wholly-Owned Subsidiary Of Nichi-Iko Commences All-Cash Tender Offer Of $21.75 Net Per Share To Acquire All Outstanding Shares Of Sagent Pharma
8/1/2016
-
Sagent Pharma Announces The Launch Of Amikacin Sulfate Injection, USP
7/18/2016
-
Japan's Nichi-Iko Takes Out Sagent Pharma for $736 Million Cash
7/11/2016
-
Sagent Pharma Forks Over $40 Million for Five ANDAs from Teva
6/16/2016
-
Sagent Pharma To Sell China Subsidiary At $50 Million Loss
1/5/2016
-
Sagent Pharma Announces The Launch Of Chlorothiazide Sodium For Injection, USP
10/27/2015
-
Sagent Pharma Reports Second Quarter 2015 Financial Results
8/4/2015
-
Sagent Pharma Appoints Ex-Teva Exec Allan Oberman as CEO
8/4/2015